Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, and public reviews. This study presents convincing findings that oligodendrocytes ...

a marker for myelinating oligodendrocytes. On the basis of these results, Demjen et al. propose that the CD95/Fas system be considered a new therapeutic target. A true understanding of how ...

‡ Relapse rate over 2 years. im.: Intramuscular; iv.: Intravenous; NA: Not available in pivotal clinical trials; p.o.: By mouth; sc.: Subcutaneous. Data taken from ...